As a widely used analgesic for upwards of 30 years, Acetaminophen is safe for both children and adults as a treatment for fever and pain. With an expiration of the brand name Ofirmev on August 5, 2017, generic possibilities abound for this unique injectable medication. The recent concern among doctors and patients regarding opioid dependence and an increase in patient tolerability to these pain medications makes a product like Acetaminophen (Ofirmev) ideal. This particular injectable form of Acetaminophen, marketed by Cadence Pharmaceuticals, is offered as a 15-minute intravenous infusion, with a maximum dose of 4000 milligrams daily. It is designed to be used adjunctively alongside an Intravenous Patient-Controlled Analgesia (PCA), such as morphine.
For patients older than age two, this unique administration of Acetaminophen has shown promise in over 20 studies and within the patient care setting. One study, which involved patients recovering from orthopedic surgery, found that the use of Ofirmev and the use of morphine offered patients a significant reduction in their pain intensity in a 24 hour period, as compared to the use of morphine with a placebo. In addition, the use of Acetaminophen (Ofirmev) and morphine significantly reduced the morphine consumption of patients, when compared to a placebo and morphine. Adverse effects of the injectable Acetaminophen were mild, and included nausea, headache and insomnia. This form of Acetaminophen is also effective as a primary treatment for pain and fever, and it should not be dispensed to patients with renal or hepatic impairment.
Postoperative patients make up a sizable portion of patients needing immediate and efficacious relief for pain. Some patients cannot receive pain medications orally or rectally, so the use of Intravenous (IV) acetaminophen is cogent. The onset of action for the brand of Acetaminophen, Ofirmev, occurs approximately 15 minutes for analgesia and within 30 minutes for antipyresis. With the peak analgesic effect being reached at the 1 hour mark, patients clearly reap the benefits of this treatment, either adjunctively or as a primary treatment for pain management.
With many post-operative patients expressing concern regarding the use of pain medications, and becoming “hooked” on them, the concomitant use of Acetaminophen and Intravenous Patient-Controlled Analgesia (PCA) is an ideal method for managing patient pain and stress after major surgery. LGM Pharma supplies this FDA approved (as of November of 2010), powerful API, Acetaminophen CAS# 103-90-2 for research and development purposes, and extends support to clients throughout the entire R&D process.
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.